---
title: "On May 9th, ZERO2IPO spent HKD 1,152 to repurchase 800 shares"
description: "According to the Zhitong Finance APP, ZERO2IPO announced that it spent HKD 1,152 to repurchase 800 shares on May 9, 2025"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/239521475.md"
published_at: "2025-05-09T09:14:03.000Z"
---

# On May 9th, ZERO2IPO spent HKD 1,152 to repurchase 800 shares

> According to the Zhitong Finance APP, ZERO2IPO announced that it spent HKD 1,152 to repurchase 800 shares on May 9, 2025

According to the Zhitong Finance APP, ZERO2IPO (01945) announced that it spent HKD 1,152 to repurchase 800 shares on May 9, 2025

### Related Stocks

- [01945.HK - ZERO2IPO](https://longbridge.com/en/quote/01945.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Standard Chartered PLC (OTCMKTS:SCBFF) Sees Significant Growth in Short Interest | Standard Chartered PLC (OTCMKTS:SCBFF) experienced a significant increase in short interest, rising 21.1% to 210,583 sha | [Link](https://longbridge.com/en/news/276119010.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |
| GRAPHIC-Climate Crossroads: A Decade After the Paris Agreement | Ten years post-Paris Agreement, climate data reveals accelerating global warming, with 2025 projected as one of the hott | [Link](https://longbridge.com/en/news/276053175.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
